Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist  by Huang, Kitty & Palma, David A.
412 Journal of Thoracic Oncology ®  •  Volume 10, Number 3, March 2015
Background: The use of stereotactic ablative radiotherapy (SABR) 
as primary treatment for early stage non–small-cell lung cancer, or 
for ablation of metastases, has increased rapidly in the past decade. 
With local recurrence rates reported at approximately 10%, and a 
patient population that is becoming increasingly fit and amenable to 
salvage treatment, appropriate multidisciplinary follow-up care is 
critical. Appropriate follow-up will allow for detection and manage-
ment of radiation-related toxicity, early detection of recurrent dis-
ease and differentiation of recurrence from radiation-induced lung 
injury.
Methods: This narrative review summarizes issues surrounding 
follow-up of patients treated with SABR in the context of a mul-
tidisciplinary perspective. We summarize treatment-related toxici-
ties including radiation pneumonitis, chest wall pain, rib fracture, 
and fatal toxicity, and highlight the challenges of early and accurate 
detection of local recurrence, while avoiding unnecessary biopsy or 
treatment of benign radiation-induced fibrotic lung damage.
Results: Follow-up recommendations based on the current evidence 
and available guidelines are summarized. Imaging follow-up rec-
ommendations include serial computed tomography (CT) imaging 
at 3–6 months posttreatment for the initial year, then every 6–12 
months for an additional 3 years, and annually thereafter. With suspi-
cion of progressive disease, recommendations include a multidisci-
plinary team discussion, the use of high-risk CT features for accurate 
detection of local recurrence, and positron emission tomography/CT 
SUV
max
 cutoffs to prompt further investigation. Biopsy and/or surgi-
cal or nonsurgical salvage therapy can be considered if safe and when 
investigations are nonreassuring.
Conclusions: The appropriate follow-up of patients after SABR 
requires collaborative input from nearly all members of the thoracic 
multidisciplinary team, and evidence is available to guide treatment 
decisions. Further research is required to develop better predictors of 
toxicity and recurrence.
(J Thorac Oncol. 2015;10: 412–419)
Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), has become a stan-
dard treatment for inoperable, early stage non–small-cell lung 
cancer (NSCLC). SABR uses highly conformal radiotherapy 
plans, with rigorous patient setup procedures, to deliver large, 
ablative doses of radiotherapy in only a few treatment sessions, 
often between 1 and 8 fractions (Fig. 1). SABR differs from 
older radiotherapy techniques in several regards: overall treat-
ment time is much shorter (usually 1–2 weeks duration versus 
4–6 weeks, respectively); the dose per fraction is much larger 
(often 18 Gy per day, rather than 2 Gy per day, respectively); 
and SABR treatment plans allow for large “hot spots” within 
the tumor, sometimes more than 150% of the prescribed dose.
These differences in treatment planning and delivery are 
associated with increased biologic potency: local control rates 
after SABR are often reported as ~90% at 3 years.1,2 In light 
of these promising outcomes, and the relative convenience 
of SABR delivery using only a few fractions in an outpatient 
setting, the use of SABR in clinical practice for treating pri-
mary lung cancers and oligometastatic disease has increased 
rapidly.3–5 These high rates of local control have led to sug-
gestions that SABR may be as effective as surgical resection 
for the primary treatment of T1N0 or T2N0 NSCLC,6 a sug-
gestion that has led to debate and the launch of randomized 
comparisons with lobectomy or wedge resection as primary 
treatment in operable patients.6,8 Unfortunately, three such 
randomized trials have closed because of a lack of accrual; 
as a result, randomized comparisons with surgery will not be 
available in the near future.
The assessment of patients after SABR is an increas-
ingly common scenario for the multidisciplinary team: not 
only are increased numbers of inoperable patients receiving 
SABR for lung cancer or oligometastatic disease but the use 
of SABR for borderline or potentially operable patients is also 
increasing.8 SABR recipients are increasingly fit with longer 
life expectancies, resulting in increased opportunity for surgi-
cal or nonsurgical salvage. For patients with local progression 
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detected after SABR, several options may be associated 
with long-term survival, including surgical resection, tar-
geted agents for patients harboring oncogene mutations, or 
in selected cases, repeat irradiation.9–11 These posttreatment 
decisions often require collaboration between members of the 
thoracic multidisciplinary team, including radiation oncolo-
gists, surgeons, radiologists, pulmonologists/respirologists, 
pathologists, and medical oncologists. This overview will dis-
cuss common clinical and radiologic findings after SABR to 
help guide these multidisciplinary decisions.
Radiation Pneumonitis after SABR
With older conventional radiotherapy techniques for 
lung cancer, reported rates of radiation pneumonitis (RP) often 
ranged from 13% to 37%.12 Symptomatic RP is characterized 
by cough or dyspnea, often accompanied with fever, chest 
discomfort and pleuritic pain, sometimes requiring oxygen 
or hospitalization. Alternative diagnoses include infection, 
chronic obstructive pulmonary disease (COPD) exacerba-
tion, recurrent tumor, lymphangitic carcinomatosis, among 
other entities,13 and in approximately 50% of cases, accurate 
diagnosis of RP is difficult.14 The standard first-line treatment 
of symptomatic RP is oral corticosteroid therapy. Response 
is usually rapid, and response rates of up to 80% have been 
reported.15 Less commonly, intravenous corticosteroids, oxy-
gen support, and hospitalization may also be required. When 
discontinuing steroid therapy, slow tapering of corticosteroid 
is important to prevent relapse of symptoms.16
Because of the relatively small lung volumes irradiated 
to high doses during SABR, the development of dyspnea or 
RP after SABR is uncommon. In a multicenter prospective 
trial of 55 patients with inoperable stage I NSCLC receiving 
SABR (RTOG 0236),17 the rate of grade 3 or 4 pulmonary 
or respiratory-tract-specific toxicity was 16%, and the rate of 
protocol-specified hypoxia or pneumonitis was 8%. In a meta-
analysis of 11 observational studies of SABR (mostly pro-
spective), the rate of severe (grade ≥ 3) RP following SABR 
was only 2%, with 0.8% of patients developing irreversible 
dyspnea.18
A recent randomized trial of 102 patients with T1 or 
T2N0 NSCLC compared stereotactic radiotherapy (66 Gy in 
three fractions) versus high-dose conventional radiotherapy 
(70 Gy in 35 fractions over 7 weeks). In the conventional arm, 
FIGURE 1.  90-year-old man with 
severe COPD (GOLD III) presents 
with a biopsy-proven left lung can-
cer, treated with stereotactic radio-
therapy (54 Gy in three fractions). 
Representative axial images corre-
spond to: A, PET/CT. B, Patient setup, 
with ConeBeam CT matched to plan-
ning CT to confirm setup accuracy. C, 
SABR treatment plan. COPD, chronic 
obstructive pulmonary disease; PET, 
positron emission tomography; CT, 
computed tomography; SABR, ste-
reotactic ablative radiotherapy.
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a 2 cm margin (compared with 0.5 cm for SABR) was added 
around the tumor to account for targeting uncertainties with 
the older technique. The trial, reported thus far in abstract form 
only, demonstrated that with these large margins, conventional 
RT was able to achieve similar local control as SABR, but 
with increased toxicity (RP rates 16% in the SABR arm ver-
sus 34% in the conventional arm). SABR was favored due to 
lower toxicity and much shorter treatment duration.19
SABR appears to be well tolerated in patients with 
severe COPD, regardless of oxygen dependence. In a retro-
spective study of 265 patients treated with SABR, the risk 
of RP ≥ Grade 1 was lower in patients with severe COPD, 
defined as a Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) score of III or IV (odds ratio [OR] of RP 
0.37 for GOLD III, compared with patients with GOLD 0, p 
< 0.01).20 Treatment-related mortality is also low: a system-
atic review of the literature comparing surgery to SABR in 
176 patients with severe COPD (defined as GOLD score III 
or IV or a predicted postoperative forced expiratory volume 
in 1 second (FEV
1
) of ≤ 40%), showed a 30-day mortality 
of 10% versus 0% respectively, favoring SABR. Local and 
locoregional control rates were excellent in all identified stud-
ies with either surgery or SABR (≥ 89%).21
Certain subgroups of patients may be at higher risk of 
RP, including patients with large tumors, and those with inter-
stitial lung disease (ILD). In a small study of 18 patients with 
large tumors (defined as a planning target volume greater than 
80 cc) treated with SABR, the crude risk of RP was 26%, and 
was closely correlated with several factors, particularly the 
volume of contralateral lung receiving a low-dose bath (≥ 5 
Gy) of radiation.22 In one study, ILD was associated with an 
increased risk of severe and fatal RP of 26% versus 3% (crude 
rates, p < 0.001).23 Because many patients with ILD are also 
at high risk of operative morbidity and mortality, SABR can 
be reasonably considered with caution after a patient discus-
sion regarding risks and benefits, and attempts to optimize a 
patient’s baseline status before treatment.
Studies reporting on effects of SABR on pulmonary 
function show only small declines in pulmonary function. A 
retrospective study of 141 patients treated with SABR who 
underwent pre- and posttreatment pulmonary function tests 
(PFTs) detected only small declines in FEV
1
 or forced vital 
capacity (FVC), with statistical significance limited to patients 
with good baseline pulmonary function (i.e., mild/moderate 
COPD).24 Nonsignificant declines in FEV
1
 were reported in 
another study of 92 patients, with declines in FEV
1
 of 1.88% 
predicted and in carbon monoxide diffusion capacity (DLCO) 
of 2.59% predicted.25 In RTOG 0236 described above, the mean 
decline in percent predicted FEV
1
 was 5.8% and in DLCO was 
6.3% at 2 years, which did not meet statistical significance. 
Furthermore, baseline PFTs did not predict pulmonary toxicity 
or overall survival.26 Patient-reported quality-of-life data also 
confirms a lack of quality-of-life decline after SABR.27
Radiographic Patterns of Lung 
Injury Following SABR
Although symptomatic RP after SABR is uncommon, 
radiographic radiation-induced lung injury (RILI) occurs 
frequently, as a result of the ablative doses of radiotherapy 
delivered to the peritumoral region. RILI can mimic a local 
recurrence (Fig. 2) both in morphologic appearance and time 
course, leading to an important clinical dilemma: how to 
accurately distinguish recurrence from fibrosis and determine 
when a biopsy or other intervention is warranted. This dis-
tinction is particularly important for an increasingly fit SABR 
patient population, where salvage options may still be con-
sidered, including surgical resection, reirradiation, combined 
chemoradiotherapy, or palliative local or systemic therapy. 
FIGURE 2.  SABR plan and follow-up 
imaging for the patient described in 
Figure 1. Serial CT chest follow-up 
were scans obtained at 3, 9, 15, 22, 
32, 35, and 39 months after radical 
treatment. The patient was not a 
candidate for salvage interventions 
and thus was monitored throughout 
without repeat biopsy. There was 
no change in RECIST measurement 
beyond 32 months. SABR, stereo-
tactic ablative radiotherapy; CT, 
computed tomography.
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Inaccurate classification as benign radiation lung injury can 
confound timely detection and delay treatment of disease pro-
gression. Alternatively, inaccurate classification of RILI as 
local recurrence can lead to unnecessary biopsy or even sal-
vage treatment with its associated risk of morbidities; biopsy 
or resection of pseudoprogression has been reported in several 
case studies in the literature.28–30
RILI can be classified as RP in the acute setting (within 
6 months of treatment), and pulmonary fibrosis in the late set-
ting (after 6 months and beyond). The degree of lung injury 
depends on multiple factors, including total dose and fraction-
ation of irradiation, along with target size.31 RILI is reported to 
occur in 62% of patients treated with SABR in the acute setting, 
and in 91% of patients in the late setting, with the majority of 
patients remaining clinically asymptomatic.32 Radiologic signs 
of fibrosis can potentially evolve even 2 years after treatment 
or beyond and does not follow a known predictable course.33
Common patterns encountered on computed tomography 
(CT) radiographic imaging have been classified as, in the acute 
setting: consolidative or ground-glass opacity changes, each 
subdivided into diffuse (greater than 5 cm) or patchy (≤ 5 cm), 
and in the late setting: modified conventional, mass-like, or scar-
like patterns.33–35 Despite this distinct range of morphologies, 
these categories are not generally used to predict recurrence. 
Furthermore, considerable interphysician variability in assess-
ments can result from the subjective nature of the current image 
evaluation criteria.36 However, familiarity with common pat-
terns of RILI may help facilitate diagnosis of local recurrence.
Challenges in Response Assessment
All follow-up imaging modalities have limitations 
in response assessment in the post-SABR setting. With CT 
alone, benign changes may appear as an evolving mass-like 
opacity, easily mistaken for local recurrence.33,37 The standard 
evaluation of tumor response by Response Evaluation Criteria 
in Solid Tumors (RECIST) 1.1 presents challenges in the post-
SABR setting, because these criteria rely on diameter alone to 
classify response, and increasing areas of fibrosis may meet 
the criteria for progressive disease. RECIST measurements 
should be done in the plane of image acquisition (axial for 
body CT).38 Positron emission tomography (PET) also has lim-
itations: acute inflammatory reaction within lung parenchyma 
exposed to ablative doses of radiation can result in falsely 
elevated metabolic activity suggestive of malignancy.39,40 PET 
is more costly than CT and is not often a routine posttreatment 
investigation at many centers; and standardized uptake value 
(SUV) measurements are not fully quantitative and are depen-
dent on more complex standardization procedures.41
Studies reporting on imaging predictors of response 
after SABR are limited by the lack of pathologic proof of 
recurrence for many patients, because of the relative frailty of 
the SABR patient population and/or the avoidance of biopsy 
where there is a lack of options for salvage in the event of 
a positive result. This lack of pathologic proof of recurrence 
may introduce bias, creating a circular argument whereby 
imaging is used to define the recurrence endpoint, and then 
the same imaging modality is investigated as a predictor of 
recurrence, overestimating the predictive ability of such tests.
A systematic review has identified certain radiographic 
high-risk features (HRFs) suggestive of recurrence after SABR 
as per Table 1.32,43 To reduce the potential bias associated with 
imaging-defined recurrences, HRFs were validated using CT 
datasets from known pathology-proven recurrences, who were 
matched to nonrecurrences, in a blinded study.43 The best HRFs 
in terms of both sensitivity and specificity were enlargement 
after 12 months and cranio-caudal growth of ≥ 5 mm and ≥ 20% 
(Table 1). The presence of three or more HRFs predicted local 
recurrence with high sensitivity and specificity (over 90%).
Functional imaging by FDG-PET can complement sus-
picious CT findings, although FDG avidity can appear tran-
siently following SABR and even persist at a low value for 
over 12 months.32 Lung injury following ablative radiother-
apy can result in transiently increased metabolically activity 
resulting in false-positive FDG avidity. Such FDG avidity may 
lead to unnecessary biopsy of benign inflammatory tissue and 
has been described as “pseudoprogression” in several case 
reports.29,44 Falsely elevated SUV
max
 readings of up to 7.0 has 
been detected shortly following SABR treatment in patients 
who ultimately were not classified as having progressive dis-
ease.45 Although the data is highly heterogeneous, a posttreat-
ment SUV
max
 ≥ 5.0, or greater than the original pretreatment 
SUV
max
 appears most suggestive of recurrent disease.32,46–48 
In another study with 17 local recurrences, SUV
max
 cutoffs as 
low as 3.2 and 4.2 have been reported, with sensitivity and 
specificity of 100% and 96–98%, respectively; however, not 
all recurrences were pathologically proven.49
Other Adverse Effects of SABR
Patients receiving SABR are also at risk of nonpul-
monary adverse effects. Approximately one-third of patients 
will experience fatigue,50 which is usually self-limiting. 
Uncommon acute or sub-acute adverse effects can include 
skin toxicity, chest wall pain (CWP), and nausea, whereas 
late effects can include ongoing CWP, rib fracture, and rarely, 
injury to the mediastinal structures when SABR is delivered 
to centrally located tumors.
The incidence of CWP and rib fracture can be miti-
gated using a risk-adapted treatment strategy, whereby the 
risk of toxicity for tumors adjacent to the chest wall can be 
minimized by giving SABR over more fractions (i.e., using 
a smaller daily dose). Based on radiobiological modeling, 
TABLE 1.  High-Risk Features on CT Predictive of  
Local Recurrence43 
High-Risk Feature Sensitivity (%) Specificity (%)
Enlarging opacity at primary site 92 67
Sequential enlargement 67 100
Enlargement after 12 months 100 83
Bulging margin 83 83
Linear margin disappearance 42 100
Loss of air bronchogram 67 96
Cranio-caudal growth of ≥5 mm 
and ≥20%
92 83
CT, computed tomography.
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smaller daily fraction sizes can substantially decrease the risk 
of late side effects.51 In a study cohort of 42 patients treated 
with stereotactic radiotherapy doses of 54–60 Gy delivered 
over only three fractions to all patients regardless of tumor 
location, high rates of chest wall toxicity were observed, with 
nine patients developing rib fracture.52 Alternatively, using a 
risk-adapted radiation treatment scheme as described above 
and delivering 55 Gy over five fractions (two additional frac-
tions) for tumors abutting the chest wall, lower toxicity rates 
have been achieved, with reported CWP and rib fracture of 
only 11.4% and 1.6%, respectively.53 A separate study of 
69 patients used a similar risk-adapted approach, deliver-
ing  either 54 Gy in three fractions, or 50–60 Gy in five frac-
tions, the latter in patients with significant chest wall dose. 
The authors report a low incidence of chest wall toxicity at 
20 months posttreatment, with chest wall pain in six patients 
(8.3%; one [1.4%] grade 3, as per CTCAE version 4.0) and rib 
fracture in five patients (6.9%).54
Fatal toxicity has been reported in the treatment of central 
tumors or tumors located within 2 cm of major structures such 
as the bronchial tree, trachea, or major vessels—accordingly 
termed the “no fly zone” in SABR—particularly when such 
tumors are treated with three-fraction regimens. These exces-
sive toxicities were most notably reported in a prospective 
phase II trial of medically inoperable early stage lung cancer 
of 70 patients, where patients were treated with the equivalent 
of approximately 54 Gy in three fractions, and the 2-year free-
dom from severe toxicity was 83% for patients with peripheral 
tumors and only 54% for patients with central tumors.55 In a 
4-year update, severe toxicities occurred in 10.4% of patients 
with peripheral tumors and 27.3% of patients with central 
tumors (p = 0.088).56 A case of central airway necrosis fol-
lowing SABR treatment to a central tumor has also been well 
described.57 The risk of severe toxicity appears to be closely 
related to dose and fractionation. In a systematic review of 
315 patients with centrally located tumors treated by SABR 
using various fractionation schemes, overall treatment-related 
mortality rate was reported at 2.7% and rates of Grade 3 or 4 
toxicities were less than 9%.58 The authors observed a dose–
response relationship for toxicity, with a 75% reduction in 
treatment-related mortality (from 2.7% to 1%) when patients 
receive a lower biologically effective dose, ≤ 210 Gy3 (a mea-
sure of the biologic effect of radiation on a particular tissue, 
taking into account radiation dose per fraction and total dose). 
In a recent study of 100 patients with centrally located tumors, 
the most common toxicity was chest wall pain (18% grade 1, 
13% grade 2) followed by RP (11% grade 2, 1% grade 3) with 
no grade 4–5 toxicity noted.59 For a more in-depth review of 
the issues regarding treatment of central tumors with stereo-
tactic radiation, the reader is referred to the relevant article in 
this IASLC series.60
Toxicities related to SABR in a reirradiation scenario, 
either as primary or salvage treatment for local recurrence, a 
secondary lung primary, or metastases, has been described in 
a limited number of small retrospective studies and in a sys-
tematic review. In a study of 39 patients who were treated with 
salvage SABR following conventional radiotherapy, 23% of 
patients had grade 2–3 RP, 3% had grade 4 skin toxicity, and 
no grade 5 toxicity was reported.61 In a similar larger study 
of 72 patients, salvage SABR following prior radiotherapy 
resulted in 20.8% of patients with severe RP (≥ grade 3), with 
one grade 5 fatality (~1%). Grade 5 toxicity rates, however, 
vary greatly among studies and fatality has been reported in as 
high as 12% of patients.62 In a repeat SABR scenario, Peulen 
et al. reported on 32 lesions in 29 patients, with 17% grade 
4–5 toxicity and 10% (n = 3) grade 5 toxicity consisting of 
massive hemoptysis. Notably, all patients with severe toxic-
ity had centrally located tumors. Overall in the systematic 
review, of 19 studies involving 466 patients that reported on 
SABR in various reirradiation scenarios, the rates of grade 
1–3 RP, grade 4 toxicity and fatal toxicity was reported in 124 
(27%), 2 (less than 1%) and 8 patients (1.7%), respectively.62 
The data suggests that toxicity may be increased in a repeat 
reirradiation scenario and repeat SABR should be considered 
with caution. Given most fatal toxicities occurred in patients 
treated for centrally located tumors, repeat irradiation of such 
lesions should be avoided or given with caution.
Toxicities following the treatment of multiple primary 
lung cancers by SABR have also been reported. In one study, 
synchronous lesions treated to a dose of 54–60 Gy in 3–8 frac-
tions were described in 56 patients, and no Grade 4–5 toxicities 
were observed after a median follow-up of 44 months.63 Given 
a favorable toxicity profile, and 85% lesional control rates, the 
authors conclude multiple SABR treatments for multiple pri-
mary lung cancers without nodal metastasis can be considered 
as a radical treatment option. Another study where SABR rep-
resented the second treatment after an index/dominant tumor 
was treated by any modality, grade ≥ three RP was also low, 
reported in 2 of 71 patients (3%).64
General Follow-Up Recommendations
Follow-up recommendations, including the frequency 
and duration of follow-up imaging for lung cancer survivors, 
are based nonrandomized studies. A retrospective study on 
the patterns of recurrence following SABR in a large cohort 
of 124 patients with disease recurrence from the Netherlands 
showed the vast majority of recurrences occurred within the 
first 3 years after treatment1; a corresponding posttreatment 
CT imaging follow-up has been proposed at 6-month intervals 
for the first 3 years, and annually thereafter.
Published consensus guidelines are also available. The 
American Association for Thoracic Surgery guidelines, appli-
cable to lung cancer survivors eligible for additional therapy, 
recommend high-resolution surveillance CT scans every 6 
months during an initial 4-year surveillance period; in the 
absence of concerning signs of recurrent disease, the fre-
quency of follow-up imaging can be reduced to an annual low-
dose screening CT, to account for the risk for a second lung 
cancer diagnosis of 3% per year.65 National Comprehensive 
Cancer Network guidelines recommend imaging surveillance 
with a chest CT scan (contrast optional) every 6–12 months for 
2 years, then a noncontrast-enhanced chest CT scan annually, 
in the absence of clinical/radiographic evidence of disease.66
Consolidating the various published guidelines as 
summarized above, a general approach to follow-up of 
patients following SABR treatment should include physi-
cal assessment every 3–6 months during the initial year 
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following treatment, followed by every 6–12 months for 3 
years, then annually thereafter. Exact frequency and dura-
tion of follow-up can be left to the discretion of the treating 
physician’s clinical assessment. For example, the presence 
of CT findings on follow-up imaging may prompt more fre-
quent imaging.
In the setting of suspicious findings on imaging, guide-
lines for follow-up of patients after SABR are currently lack-
ing. A systematic follow-up imaging algorithm based on 
HRFs and SUV
max
 thresholds based on current evidence is 
available for reference and provides literature-based guide-
lines for management until further evidence becomes avail-
able.43 This algorithm combines high-risk CT features and 
FDG-PET as tools for the prediction and accurate diagnosis 
of local recurrence. Patients are categorized as having a low-, 
intermediate-, or high-risk of recurrence based on the num-
ber of high-risk CT features present (no HRFs, 1–2 HRFs, or 
≥ 3 HRFs, respectively). Subsequent management is based 
on this risk stratification: low-risk patients with no HRFs can 
be imaged every 3–6 months for 1 year, after which an imag-
ing interval of 6–12 months can be considered; intermediate-
risk patients with the presence of 1–2 HRFs can benefit from 
an FDG-PET/CT if available and close follow-up; patients 
at high-risk of recurrence with the presence of more than 
three HRFs can be investigated with a biopsy or can pro-
ceed directly to salvage treatment. When available, SUV
max
 
values that are either greater than five, or exceeding pretreat-
ment SUV
max
 values, trigger additional interventions includ-
ing biopsy, resection, or nonsurgical salvage. Applicability 
of this follow-up scheme depends on the specific clinical 
scenario, and recommendations are expected to change as 
more data becomes available. More rigorous follow-up and 
early investigation for any suspicion of disease progression 
may also be justified in patients with known pretreatment 
risk factors for local recurrence such as larger lesions (T2), 
suboptimal radiation dose, and perhaps high pretreatment 
SUV
max
.47,67,68
Whenever possible, lung cancer patients with suspicious 
findings on radiographic follow-up scans who are amenable to 
salvage treatment should be discussed by a multidisciplinary 
team. Salvage surgery after SABR appears to be safe: at least 
four small studies have reported on patients who have under-
gone surgery for salvage of a post-SABR recurrence.69–72 
Across these four studies, such surgery is generally well toler-
ated with a favorable toxicity profile, with only one patient 
sustaining a major toxicity (fistula requiring further surgery 
for correction).71 Salvage repeat irradiation in the setting of 
SABR has shown good outcomes in terms of local control, 
and overall survival, although toxicity is likely higher, as 
described above. Reirradiation with SABR as either primary 
or salvage treatment resulted in local control rates ranging 
from 65.5% to 75% at 1 year.62
Future Directions
The results of ongoing research in response assess-
ment will continue to shape the optimal imaging and follow-
up guidelines for lung cancer patients in the coming years. 
Large studies examining patients with pathologic proof of 
recurrence would be ideal to investigate and test new imaging 
biomarkers. Given the relative uncommon clinical scenario of 
local recurrence that is confirmed pathologically, multi-insti-
tutional efforts would be required to assemble such data. New 
quantitative methods such as CT image feature analysis and 
further characterization of posttreatment FDG-PET SUVs73 
and other biologic markers are emerging.74,75 Ultimately, fur-
ther study is needed to help reduce physician uncertainties in 
imaging response assessment, which is becoming an increas-
ingly critical aspect of survivorship for patients undergoing 
SABR for NSCLC and their physicians within the multidis-
ciplinary team.
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